TrialSignal transduction and targeted therapy2025

A prospective, multicenter, comprehensive genomic profile signature study in patients with EGFR-mutant advanced non-small cell lung cancer at the first-line treatment failure of osimertinib.

Yuankai Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.